SynKIR-310 for Relapsed/Refractory B-NHL (NCT06544265)
A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
Who can join: Review the eligibility criteria below.
Location: Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute — Denver, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute — Denver, Colorado
- Winship Cancer Institute of Emory University — Atlanta, Georgia
- The University of Kansas Cancer Center — Fairway, Kansas
- Rutgers Cancer Institute — New Brunswick, New Jersey
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (267) 392-6847
Email: physician.connect@verismotherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in B Cell Lymphoma
- CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL — Houston, Texas
- Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma — Chicago, Illinois
- Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma — St Louis, Missouri
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma — Houston, Texas
Explore by condition: All B Cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.